Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Management of Heart Failure with Comorbidities

Patient Assessment

  • The European Society of Cardiology recommends that patients with heart failure and elevated cardiac biomarkers, such as BNP (2132) and troponin (163), be assessed for cardiac stress and possible myocardial injury in the setting of multiple comorbidities 1
  • Echocardiogram findings, such as preserved left ventricular function (EF 57%) with moderate mitral regurgitation and mild pulmonary hypertension (PASP 37 mmHg), are essential in evaluating heart failure patients 1, 2
  • Laboratory findings, including significant macrocytic anemia (hemoglobin 87 g/L, MCV 105) with markedly elevated B12 levels (11,325), suggest possible B12 metabolism issues in patients with heart failure and anemia 2
  • Renal function, such as CKD with an eGFR of 90 and creatinine of 52, is crucial in managing heart failure patients with comorbidities 3

Heart Failure Management

  • The European Heart Society recommends optimizing therapy for heart failure patients with preserved EF (57%) and elevated BNP, indicating heart failure that requires optimization of therapy 1, 8
  • Diuretic management should be carefully titrated to relieve congestion while monitoring renal function in heart failure patients 1, 8
  • Regular monitoring of biomarkers (BNP, troponin) and renal function is essential in elderly patients with heart failure 1, 9
  • Consider frailty assessment as it is present in >70% of heart failure patients over 80 years of age and affects treatment decisions 1, 8

Atrial Fibrillation Management

  • The European Society of Cardiology recommends rate control using beta-blockers as first-line therapy for atrial fibrillation in patients with heart failure and hypertension 4, 5
  • Anticoagulation assessment is essential as AF carries the same stroke risk regardless of whether it's paroxysmal, persistent, or permanent 4
  • Given her age (>80 years) and comorbidities (hypertension, heart failure), she is at high risk for stroke and would benefit from anticoagulation 6, 7
  • Apixaban would be a reasonable anticoagulant choice given her renal function, with dose adjustment based on age >80 years (2.5mg twice daily) 7

Monitoring and Follow-up

  • Regular follow-up with monitoring of complete blood count, renal function, and cardiac biomarkers is essential in managing heart failure patients 1, 8
  • Monitor for signs of fluid overload and adjust diuretic therapy accordingly in heart failure patients 1, 8
  • Evaluate rate control of atrial fibrillation at each visit in patients with heart failure and atrial fibrillation 4, 6

Potential Pitfalls and Caveats

  • Avoid aggressive diuresis which may worsen renal function in elderly patients with CKD and heart failure 10, 8
  • Be cautious with medication dosing in elderly patients due to altered pharmacokinetics and increased risk of adverse effects 8, 9
  • Polypharmacy is a significant concern in elderly patients; medication review to reduce unnecessary medications should be performed 8, 9

REFERENCES

9

Apixaban Dosing in Patients with DVT, Atrial Fibrillation, and Dialysis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025